¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"time factors"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 3 ÆäÀÌÁö: 1
¿µ¹® coagulation time ÇÑ±Û ÀÀ°í½Ã°£
¼³¸í   
  Ç÷¾×ÀÀ°í¶õ ÁöÇ÷ÀÇ ÇÑ °úÁ¤À¸·Î ¼¶À¯¼Ò¶õ ¹°ÁúÀ» ¸¸µé¾î ³»´Â °úÁ¤ÀÌ´Ù. ÀÌ ¼¶À¯¼Ò¶õ ¹°ÁúÀº ¼Õ»óµÈ Ç÷°üÀÇ ºÎÀ§¿¡ ÀÛ¿ëÇÏ¿© ¿©·¯ °¡Áö ¼¼Æ÷µéÀ» ¾ô¾î ¹­´Â ¿ªÇÒÀ» ÇÏ¿© °á±¹ ¼Õ»óµÈ Ç÷°ü¿¡¼­ Ç÷¾×ÀÇ ¼Ò½ÇÀ» ¸·´Â´Ù. Ç÷¾×ÀÀ°í´Â ´ÙÀ½°ú °°Àº 3´Ü°è·Î ÀÌ·ç¾îÁø´Ù.
  
  Ã¹¹øÂ° ´Ü°è´Â Ç÷°ü¼Õ»ó¿¡ ÀÇÇØ¼­ prothrombin activator¶ó´Â °ÍÀÌ ¸¸µé¾îÁö´Â ´Ü°èÀÌ´Ù. µÎ¹øÂ° ´Ü°è´Â ÀÌ prothrombin activator¶ó´Â ¹°Áú¿¡ ÀÇÇØ¼­ Ç÷¾×¼Ó¿¡ Àִ ÇÁ·ÎÆ®·ÒºóÀ̶ó´Â ¹°ÁúÀÌ Æ®·ÒºóÀ̶ó´Â ¹°Áú·Î ¹Ù²î´Â ´Ü°èÀÌ´Ù. ¼¼¹øÂ° ´Ü°è´Â Æ®·ÒºóÀ̶ó´Â ¹°Áú¿¡ ÀÇÇØ¼­ ¼¶À¯¼Ò¿øÀ̶ó´Â ¹°ÁúÀÌ ¼¶À¯¼ÒÀ¸·Î ¹Ù²î´Â ´Ü°èÀÌ´Ù.
  
  ÀÀ°íÀÛ¿ëÀº Å©°Ô 2°¡Áö·Î ³ª´µ´Âµ¥, ¿ÜÀμº ÀÀ°íÀÎÀÚ¿Í ³»Àμº ÀÀ°íÀÎÀÚ°¡ ±×°ÍÀÌ´Ù. ¿ÜÀμº ÀÀ°íÀÎÀÚ¿Í ³»Àμº ÀÀ°íÀÎÀڴ °¢±â º°°³·Î ÀÛ¿ëÇÏÁö¸¸, °á±¹Àº ¸¶Áö¸· °úÁ¤¿¡¼­ Çϳª·Î ¸¸³ª¼­ ¼¶À¯¼Ò¿øÀ» ¼¶À¯¼Ò(ÀÀ°íÀÛ¿ëÀÇ ¸¶Áö¸· ´Ü°è¿¡ »ý¼ºµÇ¸ç ´Ü´ÜÇϰí Ç®¸®Áö ¾Ê´Â ¸ÅµìÀ» Çü¼ºÇÏ¿© ÁöÇ÷ÀÛ¿ëÀ» ¿Ï¼ºÇÑ´Ù)À¸·Î ¸¸µé¾î ÀÀ°íÀÛ¿ëÀ» ³ªÅ¸³½´Ù.
¿µ¹® bleeding time ÇÑ±Û ÃâÇ÷½Ã°£
¼³¸í   
  ¸ö¿¡ »óó°¡ ³ª¼­ ÃâÇ÷ÀÌ ÀÖ¾úÀ» °æ¿ì¿¡ Çǰ¡ ¸Ü´Âµ¥ ±îÁö °É¸®´Â ½Ã°£À» ÃâÇ÷½Ã°£À̶ó°í ÇÑ´Ù. »ç¶÷ÀÇ ¸ö¿¡ »óó°¡ ³ª¼­ ÃâÇ÷ÀÌ ÀÖÀ» °æ¿ì¿¡ À̰ÍÀ» ¸·°í ÇǸ¦ ´õÀ̻󠳪Áö ¾Ê°Ô Çϴ °ÍÀ» ÁöÇ÷À̶ó°í ÇÑ´Ù. ÁöÇ÷ÀÇ °úÁ¤¿¡´Â Å©°Ô µÎ °¡Áö ´Ü°è°¡ ÀÖ´Ù. Ã¹¹øÂ° ´Ü°è´Â Ç÷¼ÒÆÇµéÀÌ »óó°¡ ³ª¼­ ¼Õ»óµÈ Ç÷°üÀÇ ºÎÀ§¸¦ ¸·´Â °ÍÀÌ´Ù. ÀÌ·¸°Ô Çϸ頿켱 Ç÷°üÀÇ ¼Õ»óºÎÀ§·ÎºÎÅÍ Çǰ¡ ³ª¿À´Â °ÍÀ» ¸·À» ¼ö°¡ ÀÖ´Ù. ´ÙÀ½ÀÇ ´Ü°è´Â »ó󸦠¸·°í Àִ Ç÷¼ÒÆÇÀ§¿¡ ¿©·¯ °¡Áö ¹°ÁúµéÀÌ ÀÛ¿ëÇØ¼­ ´õ¿í ´Ü´ÜÇϰԠÇÏ¿© »óó°¡ ³­ Ç÷°ü¿¡¼­ Çǰ¡ »õ´Â °ÍÀ» ¿µ±¸È÷ ¸·´Â °ÍÀÌ´Ù. ½±°Ô ¸»Çϸé Ç÷¼ÒÆÇÀº º®µ¹¿¡ ÇØ´çÇϴ °ÍÀÌ°í µÎ¹øÂ° °úÁ¤¿¡ Âü¿©Çϴ ¹°ÁúµéÀº ½Ã¸àÆ®¿¡ ÇØ´çÇϴ °ÍÀÌ´Ù. ÀÌ µÎ °úÁ¤ÀÌ ¿ÏÀüÇÒ °æ¿ì¿¡ ÁöÇ÷ÀÌ ¼øÁ¶·Ó°Ô ÀϾ´Ù.
  
  ÃâÇ÷½Ã°£Àº À§¿¡¼­ ¼³¸íÇÑ ÁöÇ÷ÀÇ µÎ°¡Áö °úÁ¤ Áß¿¡¼­ Ã¹¹øÂ° °úÁ¤¿¡ ÀÇÇØ¼­¸¸ ¿µÇâÀ» ¹Þ´Â´Ù. Áï ¼Õ»óµÈ Ç÷°üÀ» ¸·¾ÆÁִ º®µ¹¿¡ ÇØ´çÇϴ Ç÷¼ÒÆÇÀÇ ±â´É¸¸ Á¤»óÀÏ °æ¿ì¿¡ ÃâÇ÷½Ã°£Àº Á¤»óÀ¸·Î ³ª¿Â´Ù. ¸¸¾à Ç÷¼ÒÆÇÀÇ ±â´É¿¡ ÀÌ»óÀÌ Àִ °æ¿ì¿¡´Â ÀÚ¿¬È÷ ÃâÇ÷½Ã°£ÀÌ ±æ¾îÁø´Ù.
¿µ¹® prothrombin time ÇÑ±Û ÇÁ·ÎÆ®·Òºó½Ã°£
¼³¸í   
  ÇÁ·ÎÆ®·ÒºóÀº °£¿¡¼­ ÇÕ¼ºµÇ´Â ºñŸ¹Î K ÀÇÁ¸¼º ÀÀ°í´Ü¹éÁúÀÇ ÇϳªÀ̸ç, ÇÁ·ÎÆ®·Òºó½Ã°£Àº ¿ÜÀΰè ÀÀ°íȰ¼ºÀ» Á¾ÇÕÀûÀ¸·Î Æ¯Á¤Çϴ °Ë»çÀÇ ÇϳªÀÌ´Ù. ÇǰËÇ÷Àå¿¡ Ä®½·À̿°ú Á¶Á÷Æ®·Òº¸ÇÃ¶ó½ºÆ¾(Á¦III ÀÀ°íÀÎÀÚ)À» °¡ÇØ, ¼¶À¯¼Ò°¡ ³ªÅ¸³¯ ¶§±îÁöÀÇ ½Ã°£À¸ ÃøÁ¤ÇÑ´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • arm-to-retina circulation time
    ÆÈ¸Á¸·¼øÈ¯½Ã°£
  • atrioventricular conduction time
    ¹æ½ÇÀüµµ½Ã°£
  • acquisition time
    ȹµæ½Ã°£
  • activated coagulation time
    Ȱ¼ºÇ÷¾×ÀÀ°í½Ã°£
  • activated partial thromboplastin time
    Ȱ¼ºÈ­ºÎºÐÆ®·Òº¸ÇÃ¶ó½ºÆ¾½Ã°£
  • bleeding time
    ÃâÇ÷½Ã°£
  • bleeding time test
    ÃâÇ÷½Ã°£°Ë»ç
  • breath holding time
    ¼ûÂü´Â½Ã°£, È£ÈíÁßÁö½Ã°£
  • circulation time
    ¼øÈ¯½Ã°£
  • clot retraction time
    ÇǶ±µÞ´ç±è½Ã°£, Ç÷º´¼öÃà½Ã°£
  • clotting time
    ÀÀ°í½Ã°£
  • coagulation time
    ÀÀ°í½Ã°£
  • colonic transit time
    ´ëÀåÅë°ú½Ã°£
  • concentration-time curve
    Ç÷Áß³óµµ°î¼±
  • conduction time
    Àüµµ½Ã°£
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • time
    ½Ã°£
  • acquisition time
    ȹµæ½Ã°£
  • activated partial thromboplastin time
    Ȱ¼ºÈ­ºÎºÐÆ®·Òº¸ÇÃ¶ó½ºÆ¾½Ã°£
  • bleeding time
    ÃâÇ÷½Ã°£
  • clot retraction time
    ÇǶ±µÞ´ç±è½Ã°£, Ç÷º´ÅðÃà½Ã°£
  • coagulation time
    ÀÀ°í½Ã°£
  • colonic transit time
    ´ëÀåÅë°ú½Ã°£
  • diastolic filling time
    È®Àå±âÃæ¸¸½Ã°£
  • diffusion time
    È®»ê½Ã°£
  • expiratory pause time
    ³¯¼ûÈĽ¬´Â½Ã°£, È£±âÈÄÈÞÁö½Ã°£
  • expiratory phase time
    ³¯¼û½Ã°£, È£±â½Ã°£
  • exposure time
    ³ëÃâ½Ã°£, Æø·Î½Ã°£
  • gastric emptying time
    À§¹èÃâ½Ã°£
  • inspiratory pause time
    µé¼ûÈĽ¬´Â½Ã°£, Èí±âÈÄÈÞÁö½Ã°£
  • inspiratory phase time
    µé¼û½Ã°£, Èí±â½Ã°£
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • acquisition time
    ȹµæ½Ã°£
  • activated coagulation time
    Ȱ¼ºÇ÷¾×ÀÀ°í½Ã°£
  • activated partial thromboplastin time
    Ȱ¼ºÈ­ºÎºÐÆ®·Òº¸ÇÃ¶ó½ºÆ¾½Ã°£
  • arm-to-retina circulation time
    ÆÈ¸Á¸·¼øÈ¯½Ã°£
  • atrioventricular conduction time
    ¹æ½ÇÀüµµ½Ã°£
  • real time acquisition
    ½Ç½Ã°£È¹µæ
  • bleeding time
    ÃâÇ÷½Ã°£
  • bleeding time test
    ÃâÇ÷½Ã°£°Ë»ç
  • breath holding time
    ¼ûÂü´Â½Ã°£
  • lead-time bias
    Á¶±â¹ß°ß±â°£¹ÙÀ̾
  • clot retraction time
    Ç÷º´ÅðÃà½Ã°£, Çǵ¢À̵ڴç±è½Ã°£
  • clotting time
    (¢¡coagulation time) ÀÀ°í½Ã°£
  • coagulation time
    ÀÀ°í½Ã°£
  • concentration-time curve
    Ç÷Áß³óµµ°î¼±
  • conduction time
    Àüµµ½Ã°£
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • Insulin-like growth factors
    Àν¶¸°¾ç(å×)¼ºÀå(à÷íþ)È£¸£¸ó
  • psychological factors affecting medical condition
    ÀÇÇÐÀû»óÅ¿¡ ¿µÇâÀ» ÁÖ´Â ½É¸®Àû ¿ä¼Ò.
  • psychological factors affecting physical condition
    ½Åü»óÅ¿¡ ¿µÇâÀ» ÁÖ´Â ½É¸®Àû ¿ä¼Ò.
  • quality factors
    Ư¼º ¿ä¼Ò, Áú ¿ä¼Ò
  • AUC : area under the concentration-time curve
    Ç÷Áß(¾à¹°)³óµµ°î¼±ÇϸéÀû.
  • BUT->breakup time of tear film
    ´«¹°¸·ÆÄ±«½Ã°£, ´©¾×¸·ÆÄ±«½Ã°£
  • Conduction time
    Àüµµ½Ã°£
  • MTT=£¾mean tidal time
    Æò±Õ¼øÈ¯½Ã°£.
  • Russells viper venom time
    ·¯¼¿¹ÙÀÌÆÛº£³ð½Ã°£
  • T.G.C (time gain compensation)
    ½Ã°£ (ãÁÊà) °ÔÀÎ º¸»ó (ÜÍßÁ), °Å¸®(±íÀÌ) °ÔÀÎ º¸»ó
  • T.G.C (time gain compensation)
    ½Ã°£ °ÔÀÎ º¸»ó
  • T1 relaxation time
    T1 ÀÌ¿Ï ½Ã°£
  • T2 (spin spin) relaxation time
    T2(½ºÇɽºÇÉ) À̿Ͻð£
  • T2 relaxation time
    T2 ÀÌ¿Ï ½Ã°£
  • TM scan(Time motion)
    ½Ã°£ ¿îµ¿ ¹æ½Ä
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • coagulation factors
    ÀÀ°íÀÎÀÚ(¡­ì×í­)
  • exogenous factors
    ¿ÜÀμº ¿ä¼Ò(èâì×àõ é©áÈ).
  • exogenous factors
    ¿ÜÀμº ¿ä¼Ò(¡­é©áÈ).
  • factors
  • psychological factors affecting medical condition
    ÀÇÇÐÀû»óÅ¿¡ ¿µÇâÀ» ÁÖ´Â ½É¸®Àû ¿ä¼Ò.
  • psychological factors affecting physical condition
    ½Åü»óÅ¿¡ ¿µÇâÀ» ÁÖ´Â ½É¸®Àû ¿ä¼Ò.
  • quality factors
    Ư¼º ¿ä¼Ò, Áú ¿ä¼Ò
  • risk factors
  • tissue growth factors
  • acquisition time
    ȹµæ ½Ã°£
  • activated clotting time
    Ȱ¼ºÈ­ÀÀ°í½Ã°£
  • activated coagulation time(ACT)
    Ȱ¼º Ç÷¾× ÀÀ°í½Ã°£
  • activated coagulation time=ACT
    Ȱ¼ºÈ­ ÀÀ°í½Ã°£
  • activated partial prothrombin time
    Ȱ¼º ºÎºÐÇÁ·ÎÆ®·Òºó½Ã°£
  • activated partial thromboplastin time
    Ȱ¼º ºÎºÐÆ®·Òº¸ÇÃ¶ó½ºÆ¾½Ã°£
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • fibroblast growth factors
    ¼¶À¯¾Æ¼¼Æ÷ ¼ºÀÚÀÎÀÚ (àéë«ä´á¬øàà÷íþì×í­)
  • suppressor factors
    ¾ï¾Ð(ÀÚ) ÀÎÀÚ(åääâ(í­)ì×í­)
  • assimilation time
    µ¿È­ÀÛ¿ë ½Ã°£ (ÔÒûùíÂéÄãÁÊà)
  • clotting time
    ÀÀ°í½Ã°£(ëêͳãÁÊà)
  • coincidence time
    µ¿½Ã½Ã°£(ÔÒãÁãÁÊà)
  • double beam in time spectrophotometer
    ½Ö±¤¼Ó ½Ã°£ ºÐ±¤±¤µµ°è(äªÎÃãÁÊàáÜÝÂÎÃÎÃÓøÍª)
  • elution time
    ¿ë¸® ½Ã°£ (éÁ×îãÁÊà)
  • fixed time assay
    ÀÏÁ¤½Ã°£(ìéïÒãÁÊà) ¾Æ½êÀÌ
  • generation time
    ¼¼´ë ½Ã°£(á¦ÓÛãÁÊà)
  • generation-time hypothesis
    ¼¼´ë ½Ã°£ ¼³(á¦ÓÛãÁÊààã)
  • half-reaction time
    ¹Ý¹ÝÀÀ ½Ã°£(ÚâÚãëëãÁÊà)
  • half-time
    ¹Ý ½Ã°£(ÚâãÁÊà)
  • high-temperature-short-time method
    °í¿Â ´Ü½Ã°£¹ý(ÍÔè®Ó­ãÁÊàÛö)
  • mean generation time
    Æò±Õ¼¼´ë±â°£(øÁгá¦ÓáÑ¢Êà)
  • recovery time
    ȸ¼ö ½Ã°£(üÞâ¥ãÁÊà)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • quality factors
    Ư¼º¿ä¼Ò, Áú¿ä¼Ò
  • acquisition time
    ȹµæ½Ã°£
  • arm to lung time test
    ÆÈÆó¼øÈ¯½Ã°£½ÃÇè
  • correlation time
    »ó°ü½Ã°£
  • data acquisition time
    ÀÚ·áȹµæ½Ã°£
  • delay time
    Áö¿¬½Ã°£
  • diffusion time
    È®»ê½Ã°£
  • doubling time
    ¹è°¡½Ã°£
  • echo time [=TE]
    ¿¡Äڽð£
  • elapsed time
    °æ°ú½Ã°£
  • exposure time
    ³ëÃâ½Ã°£, Á¶ ½Ã°£
  • fast time constant circuit
    °í¼Ó½Ã°£°íÁ¤È¸·Î
  • gastric emptying time
    À§¹èÃâ½Ã°£
  • half-life; half-time
    ¹Ý°¨±â
  • intercostal real-time scanning
    ´Á°£ ½Ç½Ã°£½ºÄµ
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
CT calcitonin; calf testis; cardiac tamponade; cardiothoracic [ratio]; carotid tracing; carpal tunnel; ...
PTT partial thromboplastin time; particle transport time; posterior tibial tendon (transfer); prothrombi...
ST esotropia; scala tympani; scaphotrapezoid; sclerotherapy; sedimentation time; semitendinosus; sensor...
TT tablet triturate; tactile tension; tendon transfer; test tube; testicular torsion; tetanus toxin; te...
CRT cadaveric renal transplant; cardiac resuscitation team; cathode-ray tube; certified; Certified Recor...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
TE time , expiratory time
AEF Allogeneic effect factors
APF Anti-perinuclear factors
CF Clastogenic factors
DMF Dose modification factors
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • controlling factors in facial growth
    ¾È¸é ¼ºÀåÀÇ Á¶Àý ¿äÀÎ
  • acquisition time
    ȹµæ ½Ã°£
  • activated coagulation time
    Ȱ¼º Ç÷¾× ÀÀ°í½Ã°£
  • area under the concentration-time curve
    Ç÷Áß ³óµµ °î¼±ÇÏ ¸éÀû, Ç÷Áß ¾à¹° ³óµµ °î¼±ÇÏ ¸éÀû
  • arm to lung time test
    ÆÈ Æó ¼øÈ¯ ½Ã°£ ½ÃÇè
  • arm-to-retina circulation time
    ÆÈ ¸Á¸· ¼øÈ¯ ½Ã°£
  • bleeding time test
    ÃâÇ÷ ½Ã°£ ½ÃÇè
  • chair time
    Áø·á ½Ã°£, Ä¡·á ½Ã°£
    ȯÀÚ°¡ Áø´Ü ¹× Ä¡·á ¹Þ±â À§ÇÑ ½Ã°£.
  • change over time
    ½Ã°£¿¡ µû¸¥ º¯È­
  • coagulation time
    ÀÀ°í ½Ã°£
  • contact time
    Á¢ÃË ½Ã°£
  • correlation time
    »ó°ü ½Ã°£
  • doubling time
    ¹è°¡ ½Ã°£
  • echo time
    ¿¡ÄÚ ½Ã°£
  • exposure time per session
    ´ÜÀ§´ç ³ëÃ⠽ð£
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
time factors Elements of limited time intervals, contributing to particular results or situations.
(12 Dec 1998)
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
age factors Age as a constituent element or influence contributing to the production of a result. It may be applicable to the cause or the effect of a circumstance. It is used with human or animal concepts but should be differentiated from aging, a physiological process, and time factors which refers only to the passage of time.
(12 Dec 1998)
bacteriocin factors Bacterial plasmid's responsible for the elaboration of bacteriocins.
Synonym: bacteriocin factors, bacteriocinogens.
(05 Mar 2000)
B-cell differentiation/growth factors Various substances, usually obtained from the supernatant of T-cell cultures, such as interleukin 4, 5, and 6. These substances are necessary for B-cell growth, maturation, and differentiation into plasma cells or B memory cells.
(05 Mar 2000)
biological factors Compounds made by living organisms. They have biological or physiological activities.
(12 Dec 1998)
biotic factors Environmental factor's or influences resulting from the activities of living organisms, as contrasted to those resulting from climatic, geological, or other factor's.
(05 Mar 2000)
blood coagulation factors Endogenous substances, usually proteins, that participate in the blood coagulation process.
(12 Dec 1998)
macrophage migration-inhibitory factors Proteins released by sensitised lymphocytes and possibly other cells that inhibit the migration of macrophages away from the release site. The structure and chemical properties may vary with the species and type of releasing cell.
(12 Dec 1998)
recognition factors Factors which effect "recognition" of target antigens by polymorphonuclear leukocytes; apparently the Fc portion of antibody molecules and the activated third component of complement (C3), for both of which phagocytes have receptor sites.
(05 Mar 2000)
glaucoma, risk factors If you belong to a high-risk group for glaucoma, have your eyes examined through dilated pupils every 2 years by an eye care professional. High-risk groups include everyone with a family history of glaucoma, everyone over the age of 60 and any Black over the age of 40. (Among Blacks, studies show that glaucoma is: 5 times more likely to occur in Blacks than in Whites and about 4 times more likely to cause blindness in Blacks than in Whites).
(12 Dec 1998)
releasing factors Hormones produced by the hypothalamus whichstimulate the release of other hormones in the pituitary gland.
(09 Oct 1997)
resistance factors Plasmid's carrying genes responsible for antibiotic (or antibacterial drug) resistance among bacteria (notably Enterobacteriaceae); they may be conjugative or nonconjugative plasmid's, the former possessing transfer genes (resistance transfer factor) lacking in the latter.
Synonym: R factors, R plasmids, resistance factors, resistance-transferring episomes.
(05 Mar 2000)
peptide elongation factors Protein factors uniquely required during the elongation phase of protein synthesis.
(12 Dec 1998)
peptide initiation factors Protein factors uniquely required during the initiation phase of protein synthesis.
(12 Dec 1998)
peptide termination factors Proteins that are exclusively involved in the termination reactions of protein synthesis on the ribosome.
(12 Dec 1998)
C factors Proteins that restore phosphorylating ability to mitochondria that have lost it, i.e., have become "uncoupled" so that oxidation and electron transport no longer produces ATP. Usually termed coupling factor F1, F2, etc.
Synonym: C factors.
(05 Mar 2000)
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 1 ÆäÀÌÁö: 1
  • Time Factors - »õâ Elements of limited time intervals, contributing to particular results or situations.
    Synonyms : Factor, Time, Factors, Time, Time Factor
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • all the time
    ±×µ¿¾È Á×,(¹Ì)¾ðÁ¦³ª
  • any time
    ¾ðÁ¦µçÁö
  • at a time
    Çѹø¿¡,µ¿½Ã¿¡
  • at any time
    ¾ðÁ¦¶óµµ
  • at that time
    ±×¶§,±×´ç½Ã
  • at the same time
    µ¿½Ã¿¡
  • at this time of ~
    ~ÀÇ À̸¾¶§
  • behind time
    ´ÊÀº
  • bide one's time
    ÁÁÀº½Ã±â¸¦ ±â´Ù¸®´Ù
  • by that time
    ±×¶§±îÁö
  • by the time
    ±×¶§Âë¿¡
  • by-time
    ¿©°¡
  • for the first time
    óÀ½À¸·Î
  • high time
    ²À ¾Ë¸ÂÀº ¶§
  • in time
    ½Ã°£¿¡ ¸Â°Ô
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á